๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia

โœ Scribed by Toma, S.; Mangiante, P.E.; Margarino, G.; Nicolo, G.; Palumbo, R.


Book ID
123296949
Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
378 KB
Volume
28
Category
Article
ISSN
0964-1955

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Transforming growth factor ฮฑ (TGF-ฮฑ) exp
โœ Samuel W. Beenken; Marty T. Sellers; Peter Huang; Glenn Peters; Helen Krontiras; ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 152 KB

Background. Surrogate endpoint biomarkers (SEBs) are detectable molecular, cellular, and tissue changes that take place during tumorigenesis and can be modulated by a chemoprevention agent. Method. To identify candidate SEBs for invasive squamous cell carcinoma of the upper aerodigestive tract (SCC

Reduction of bacterial skin flora during
โœ Arthur Weissmann; Annemarie Wagner; Gerd Plewig ๐Ÿ“‚ Article ๐Ÿ“… 1981 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 253 KB

Recently, a new promising compound for the oral treatment of acne and other dermatologic disorders became available [7,8]. This substance, 13-cis retinoic acid (Ro 4-3780), is presently being evaluated in clinical trials. A group of 18 patients with severe acne, unresponsive to previous treatment, p